Study: No benefit from intermittent therapy in prostate cancer

04/4/2013 | HealthDay News

Patients with metastatic prostate cancer who received intermittent androgen deprivation therapy had a 10% greater risk of mortality than those who got continuous hormone treatment, according to a study published in the New England Journal of Medicine. Researchers tracked more than 1,500 patients and found average survival rates of 5.8 years for the continuous therapy group and 5.1 years for the intermittent treatment group. Men who received intermittent treatment initially reported better quality of life and mental health, but those gains were lost by the end of the study.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA